Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas:Propensity Score-Matched Analysis of Centers in the Netherlands and Belgium

The value of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneally metastasized goblet-cell carcinoids (GCCs) and mixed adenoneuroendocrine carcinomas (MANECs) is unclear. In a large propensity-matched cohort of patients with peritoneally metastasized GCCs and MANECs, CRS-HIPEC was significantly associated with improved survival compared to surgery alone. Such treatment is supported in expert centers offering this multimodal treatment. Background: The value of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (H... Mehr ...

Verfasser: Sluiter, Nina R.
van der Bilt, Jarmila D.
Croll, Dorothee M. R.
Vriens, Menno R.
de Hingh, Ignace H. J. T.
Hemmer, Patrick
Aalbers, Arend G. J.
Bremers, Andreas J. A.
Ceelen, Wim
D'Hoore, Andre
Schoonmade, Linda J.
Coupe, Veerle
Verheul, Henk
Kazemier, Geert
Tuynman, Jurriaan B.
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Reihe/Periodikum: Dutch Peritoneal Oncology Grp , Sluiter , N R , van der Bilt , J D , Croll , D M R , Vriens , M R , de Hingh , I H J T , Hemmer , P , Aalbers , A G J , Bremers , A J A , Ceelen , W , D'Hoore , A , Schoonmade , L J , Coupe , V , Verheul , H , Kazemier , G & Tuynman , J B 2020 , ' Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas : Propensity Score-Matched Analysis of Centers in the Netherlands and Belgium ' , Clinical Colorectal Cancer , vol. 19 , no. 3 , pp. E87-E99 . https://doi.org/10.1016/j.clcc.2020.01.002
Schlagwörter: Colorectal cancer / Cytoreductive surgery / Gastrointestinal neoplasm / Peritoneal metastases / COLORECTAL PERITONEAL METASTASES / ENETS CONSENSUS GUIDELINES / NEUROENDOCRINE TUMORS / SYSTEMIC CHEMOTHERAPY / PATIENT SELECTION / RANDOMIZED-TRIAL / NEOPLASMS / SURVIVAL / CLASSIFICATION / MANAGEMENT
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28954978
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/4a4b8ec5-c611-44c6-8674-dad4c9b492ba

The value of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneally metastasized goblet-cell carcinoids (GCCs) and mixed adenoneuroendocrine carcinomas (MANECs) is unclear. In a large propensity-matched cohort of patients with peritoneally metastasized GCCs and MANECs, CRS-HIPEC was significantly associated with improved survival compared to surgery alone. Such treatment is supported in expert centers offering this multimodal treatment. Background: The value of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneally metastasized goblet-cell carcinoids (GCCs) and mixed adenoneuroendocrine carcinomas (MANECs) is currently unclear. We compared outcomes of CRS-HIPEC to surgery alone for peritoneally metastasized GCCs and MANECs. Patients and Methods: Two cohorts were obtained from the Netherlands Cancer Registry (n = 569): patients with peritoneally metastasized GCCs and MANECs treated with CRS-HIPEC in Dutch and Belgian centers (n = 45), and patients treated with surgery alone. Primary outcome was overall survival (OS). Secondary outcomes were morbidity and hospital mortality. After propensity score matching, OS was compared in univariate and multivariate analyses. A systematic literature review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines from database inception to June 25, 2018. Results: After matching for sex, tumor stage, lymph node stage, and liver metastases, CRS-HIPEC was associated with improved median OS in the combined GCC and MANEC group and the separate GCC subgroup in univariate (GCC + MANEC: 39 vs. 12 months, P